전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved166 programs
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

nivolumab (Opdivo, NAI + Nivolumab + Ipilimumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, NAI + Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
AntibodyLimited DatastaleWashington University School of…Phase 2

Nogapendekin alfa inbakicept (Nogapendekin alfa inbakicept)

Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent · Non-small Cell Lung Cancer Stage IV

#Non-smallCellLungCancerStageIV#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerRecurrent+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssistance Publique Hopitaux De…Phase 2

MEDI9447 (Oleclumab, Oleclumab (MEDI9447))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Assistance
Trials 1Status Recruiting
AntibodyLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

PD-1 mAb (PD-1 mAb)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#LungNeoplasmMalignant+2
Trials 1Status Active
AntibodyLimited DatastaleAmgenPhase 2

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+1
Trials 1Status Active
AntibodyLimited DatastaleMerus B.V.Phase 2

pembrolizumab (Keytruda, Petosemtamab + Pembrolizumab)

Lung Cancer - Non Small Cell Squamous; Lung Cancer - Non Small Cell Non-Squamous · Lung Cancer - Non Small Cell Squamous

#LungCancer-NonSmallCellSquamous#Antibody#Phase2#monoclonal-antibody#LungCancer-NonSmallCellNon-Squam+1
Trials 1Status Recruiting
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleSWOG Cancer Research NetworkPreclinical

Rilotumumab (Rilotumumab)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#Antibody#Preclinical#monoclonal-antibody#StageIVSquamousCellLungCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Discontinued
ADCLimited DatastaleLi-kun ChenPhase 2

sacituzumab govitecan (Trodelvy, Sac-TMT, Sacituzumab tirumotecan, Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Li-kun
Trials 1Status Recruiting
ADCLimited DatastaleTianjin Medical University Canc…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Tianjin
Trials 1Status Recruiting

7 / 9 pages

← PreviousNext →